Ilenia Calcaterra: Clinical Relevance of Persistent Pain in Emicizumab-Treated Haemophilia A
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared a post on LinkedIn:
“Honored to have presented our work during the free paper session at the WFH 2026 World Congress in Kuala Lumpur.
In this study, we explored the multidimensional pain experience of adults with severe haemophilia
A receiving Emicizumab prophylaxis using the Multidimensional Haemophilia Pain Questionnaire (MHPQ).
Our findings highlight an important clinical message: even in the era of highly effective bleed prevention, pain remains prevalent and functionally relevant, suggesting that haemophilia-related pain is not exclusively bleeding-driven and deserves structured, multidimensional assessment in routine care.
Grateful for the opportunity to share our data, for the stimulating scientific discussion, and for the chance to contribute to ongoing research aimed at improving the lives of people with haemophilia.”
Other posts featuring Ilenia Calcaterra on Hemostasis Today.
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI
-
Sep 20, 2026, 09:51Ceasovschih Alexandr: A Closer Look at Lipid Disorders in CKM Syndrome
-
Sep 20, 2026, 09:05World Stroke Academy: Can Adjunct IAT Improve Tissue Reperfusion?
-
Sep 20, 2026, 06:46Neeraj Songara: From Donated Blood to Engineered Therapeutics
-
Sep 20, 2026, 06:24Louise St. Germain Bannon: Improving Awareness and Care for Women Across the Lifespan
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?